SEOUL -- China's regulatory body has approved a drug developed by GC Pharma, a biotech company in South Korea, for the long-term treatment of patients with Hunter syndrome, a rare, inherited disorder in which the body does not properly digest sugar molecules.
GC Pharma said Hunterase has acquired approval from the National Medical Products Administration. An application has been made through CANBridge Pharmaceuticals, which is in charge of Hunterase's development and commercialization in China.
"It is very meaningful in that (Hunterase) can provide new treatment environments and opportunities for patients with Hunter Syndrome in China," GC Pharm CEO Huh Eun-chul said. Hunter Syndrome occurs more frequently in Asian countries. It causes abnormalities in many organs, including the skeleton, heart, and respiratory system, leading to death in severe cases.
GC Pharma has promoted Hunterase for the treatment of severe hunter syndrome patients who gradually lose their cognitive ability and have a very short life expectancy, saying the drug has significantly reduced heparan sulfate, a core substance that causes central nerve damage.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.